Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REVUMENIB vs REZAFUNGIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REVUMENIB vs REZAFUNGIN: Safety Overview

Metric REVUMENIB REZAFUNGIN
Total FAERS Reports 371 108
Deaths Reported 49 12
Death Rate 13.2% 11.1%
Hospitalizations 93 20
Average Patient Age 46.4 yrs 53.8 yrs
% Female Patients 47.6% 54.3%
FDA Approval Date Nov 15, 2024 Mar 22, 2023
Manufacturer Syndax Pharmaceuticals, Inc. Melinta Therapeutics, LLC
Route ORAL INTRAVENOUS
Marketing Status Prescription Prescription